Annual Wellness Visit for Neurologists — Cognitive Screening, ADL Assessment, and Functional Staging
Neurologists conducting Annual Wellness Visits require more than basic cognitive screening — they need functional staging data, ADL and IADL assessment, and early detection of neurological conditions before symptoms are clinically obvious. GIA® by Scienza Health screens for 46 conditions from a 40-second natural conversation and administers ADL and IADL assessments with automated EHR write-back.
Cognitive Screening for Neurologists at the AWV
Neurologists conducting Annual Wellness Visits need cognitive screening that surfaces early Parkinson’s, cognitive decline, and mild cognitive impairment before symptoms are clinically obvious. GIA® analyzes 2,500+ speech biomarkers from a 40-second conversation. Published AUC figures include Parkinson’s disease at AUC 0.97 and cognitive decline at AUC 0.890.
ADL and IADL Assessment at the Neurological AWV
Functional staging is essential for neurologists managing patients with Parkinson’s disease, multiple sclerosis, and cognitive decline. GIA® administers ADL assessments (Barthel Index, Katz Index) and IADL assessments (Lawton Scale, FIM) during the patient interaction — providing functional staging data alongside cognitive screening results in the same workflow.
Conditions GIA® Screens for at the Neurological AWV
- Parkinson's disease (AUC 0.97)
- Cognitive decline (AUC 0.890)
- Mild cognitive impairment
- Alzheimer's disease
- Depression (AUC 0.816)
- Anxiety (AUC 0.775)
- Sleep disorders
- And 39+ additional conditions
See the full 46-condition list →
Frequently Asked Questions
What cognitive screening tools do neurologists use at the AWV?
Neurologists commonly use MoCA, MMSE, and Mini-Cog for cognitive screening at the AWV. GIA® by Scienza Health screens for 46 conditions including Parkinson's disease (AUC 0.97) and cognitive decline (AUC 0.890) from a 40-second natural conversation with results in the EHR in under 2 minutes.
Can AI screen for Parkinson's disease at the AWV?
GIA® by Scienza Health screens for Parkinson's disease risk using speech biomarkers with AUC 0.97 in peer-reviewed validation. Results are delivered to the clinician's EHR for review. GIA® does not diagnose Parkinson's disease — it identifies early risk signals for clinician review.
How does ADL assessment support neurological AWV workflows?
ADL and IADL assessment provides functional staging data alongside cognitive screening. GIA® administers Barthel Index, Katz Index, Lawton Scale, and FIM during the patient interaction with automated EHR write-back — supporting functional staging for neurological conditions including Parkinson's disease and cognitive decline.
Can neurologists bill for annual wellness visits?
Yes. Neurologists who serve as a Medicare patient's primary care provider or who conduct the AWV can bill using G0438 (initial AWV) or G0439 (subsequent AWV). The AWV must include all required components including cognitive impairment detection. Verify eligibility and documentation requirements with your billing team. Reimbursement rates vary by locality — verify current rates at cms.gov.
How do you assess ADLs in Parkinson's disease patients during an AWV?
ADL assessment in Parkinson's patients during the AWV provides functional staging data that complements cognitive screening. The Barthel Index and Katz Index are commonly used. GIA® by Scienza Health administers ADL assessment instruments during the patient interaction and writes structured results to the EHR — alongside cognitive screening that includes Parkinson's disease risk detection at AUC 0.97 in peer-reviewed validation. All results require clinician review.